EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines
Cheryl A. Hawkes, Mark Eccleston, Irene Fischetti, Vera Mongiardini et al.
Citations
3 citations
Journal
Epigenomics
Topics
Epigenetics and DNA Methylation
Field-Weighted Citation Impact (FWCI)
2.42
article
EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines
Cheryl A. Hawkes, Mark Eccleston, Irene Fischetti, Vera Mongiardini, Massimiliano Manzo, Francesco Crea, Maryam Latarani, Elena Jachetti, Sushilaben H. Rigas, Ilaria Alborelli, Namra Mahmood, Priyadarsini Gangadharannambiar, Shusuke Akamatsu, Mario P. Colombo, Benedetto Grimaldi, Perla Pucci, Yuzhuo Z. Wang
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
EpigenomicsVol. 17(3)
Institutions
University of British Columbia (CA), University of Basel (CH), The Open University (GB), University of Cambridge (GB), University Hospital of Basel (CH), Italian Institute of Technology (IT), ValiRx (United Kingdom) (GB), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Nagoya University (JP), Lancaster University (GB)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
EZH2 inhibition enhances the activity of Carboplatin in aggressive-variant prostate cancer cell lines — Cheryl A. Hawkes, Mark Eccleston, et al. · Epigenomics (2025) | TGRS Research Map | TGRS